Phil Ferneau

Phil Ferneau has been involved in the venture capital and investment space since 2002, when they co-founded and became the Managing Partner of Borealis Ventures. In 2008, they became an Investor with Adimab, and since then has held Investor roles with Evox Therapeutics Ltd (2018), Orbit Discovery (2018), Ovation.io (2019), T-Cypher Bio (2020), Amagma Therapeutics (2020), Ankyra Therapeutics (2021), and Compass Therapeutics LLC (2014). Additionally, they have held Board Director and Investor roles with Orbit Discovery (2018), Ovation.io (2019), T-Cypher Bio (2020), Amagma Therapeutics (2020), and Ankyra Therapeutics (2021), as well as a Board Observer and Investor role with Teckro (2018).

Phil Ferneau received their MBA from The Tuck School of Business at Dartmouth, an A.B. in Government from Dartmouth College, and a J.D. in Law from the University of Virginia School of Law.